Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna (MRNA) receives provisional approval in Australia for its Omicron-containing bivalent booster vaccine mRNA-1273.214 in adults, making it the first bivalent COVID-19 vaccine approved for use in Australia.

Moderna's (MRNA) Omicron Based Jab gets Approval in Australia

BioNTech SE

Novavax

Pfizer

They still might offer solid long-term opportunities for investors.

After Double-Digit Percentage Declines, Are Vaccine Stocks Buys?

Australia becomes among the first countries in the world to approve the use of a next-generation bivalent COVID-19 vaccine mRNA-1273.214, an Omicron-containing bivalent vaccine, has demonstrated significantly higher antibody titers against all tested variants, including Omicron BA.1 and BA.4/5 subvariants Moderna expects to supply mRNA-1273.214 to Australia in September CAMBRIDGE, MA / ACCESSWIRE / August 30, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional approval for its Omicron-containing bivalent booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron) as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains 25 µg of mRNA-1273 (Spikevax) and 25 µg of a vaccine candidate targeting the Omicron variant of concern (BA.1).

Therapeutic Goods Administration Provisionally Approves Moderna's Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia

Is Moderna stock a buy after asking the FDA to sign off on its BA.4- and BA.5-tailored Covid booster? Is MRNA stock a buy now?

Is Moderna Stock A Buy As FDA Mulls Its Updated Covid Booster Shot?

Moderna (MRNA) sues Pfizer and BioNTech, alleging that Comirnaty infringes on patents that Moderna filed from 2010 to 2016 related to its mRNA technology.

Moderna (MRNA) Sues Pfizer and BioNTech Over COVID Jab

Discover

Diamondback Energy

Intercontinental Exchange

Mastercard

Signature Bank

Visa

VeriSign

Imagine companies three times as profitable as the S&P 500 — putting them in a good position to handle whatever comes next. The post The 8 Most Profitable U.S. Companies Practically Print Money appeared first on Investor's Business Daily.

The 8 Most Profitable U.S. Companies Practically Print Money

CAMBRIDGE, MA / ACCESSWIRE / August 29, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will host its in-person and virtual R&D Day at 9:00 a.m. ET on Thursday, September 8, 2022.

Moderna to Host R&D Day on Thursday, September 8, 2022

Moderna Inc. MRNA, -3.77% said Monday the Swiss regulator has granted temporary authorization to its bivalent omicron-targeting COVID booster for use in adults aged 18 and older. "Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains 25 ug of mRNA-1273 (Spikevax) and 25 ug of a vaccine candidate targeting the Omicron variant of concern (BA.1)," the company said in a statement.

Swiss regulator grants temporary authorization for Moderna bivalent COVID booster for adults age 18 and older

Switzerland becomes among the first countries in the world to approve the use of a next-generation bivalent COVID-19 booster vaccine Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273 Moderna is working with Swissmedic and the Government of Switzerland to make mRNA-1273.214 available in early September CAMBRIDGE, MA / ACCESSWIRE / August 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic has granted temporary authorization for the use of Moderna's Omicron-targeting bivalent booster vaccine, Spikevax Bivalent Original/Omicron (mRNA-1273.214) for active immunization to prevent SARS-CoV-2 virus-induced Coronavirus-2019 disease for individuals aged 18 years and older. Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains 25 µg of mRNA-1273 (Spikevax) and 25 µg of a vaccine candidate targeting the Omicron variant of concern (BA.1).

Swissmedic Authorizes Moderna's Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214

These vaccine leaders are set to target the latest coronavirus variant.

Better COVID Booster Stock: Moderna vs. Pfizer

Moderna's complaint is focused on two critical innovations.

Could This Move by Moderna Cost Pfizer Billions?

Moderna is suing Pfizer and BioNTech over patents it said it filed years ago on the life-saving technology.

Moderna Sues Pfizer Over mRNA Technology Used in COVID Vaccines

Moderna filed a lawsuit against Pfizer and BioNTech claiming the biopharmaceutical companies infringed on Moderna's patents related to mRNA technology in develop of their COVID-19 vaccine. The lawsuit, to be filed in the U.S.

Moderna sues Pfizer, BioNTech over alleged mRNA patent infringement

Moderna Inc. on Friday filed lawsuits against Pfizer Inc. and German partner BioNTech SE, alleging the pair infringed patents relating to its mRNA platform, a key technology behind all of their COVID vaccines.

Moderna sets up clash with Pfizer and BioNTech with patent lawsuits in the U.S. and Germany

Pfizer /BioNTech and Moderna have been hit with patent lawsuits by other companies related to their COVID-19 vaccines.

Factbox-Moderna sues Pfizer as patent owners fight over mRNA vaccine technology

Some 16 million Americans of working age have long-term COVID and about 2 to 4 million are not working as they struggle with their symptoms, according to a new report from the Brookings Institution.

Report finds Americans losing up to $1 billion in wages from long COVID, and Moderna sues Pfizer and BioNTech over mRNA patents

Moderna alleges Pfizer and its German partner BioNTech copied their mRNA technology while developing their COVID-19 vaccine.

Moderna sues Pfizer and BioNTech for patent infringement over COVID vaccine

The company says Pfizer and BioNTech copied Moderna's mRNA technology without its permission.

Moderna Sues Pfizer And BioNTech Over Covid-19 Vaccine

Moderna is suing Pfizer and BioNTech for patent infringement, claiming the duo copied its mRNA technology. All three vaccine stocks fell.

Moderna Claims Pfizer, BioNTech Stole Its Patented Tech In Covid Shot

Moderna is suing competing vaccine maker Pfizer and its German partner BioNTech, alleging the pharmaceutical companies copied its technology.

Moderna sues Pfizer after saying it wouldn't enforce its patents for COVID-19 vaccine technology

Moderna is suing Pfizer and its German partner BioNTech for alleged patent infringement in the development of the first COVID-19 vaccine approved in the US.

Moderna sues Pfizer/BioNTech over COVID vaccine

In a lawsuit filed in federal court in Massachusetts, Moderna is claiming that its competitors' Covid-19 vaccine infringes on five patents.

Moderna Sues Pfizer, BioNTech for mRNA Patent Infringement

Moderna Inc. MRNA, +0.44% said Friday it is suing Pfizer Inc. PFE, +0.99% and German partner BioNTech SE BNTX, +1.59% for infringing patents relating to its mRNA platform, the source of the COVID vaccines developed by the three parties. The suit is to be filed Friday in the U.S. District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany.

Moderna sues Pfizer and BioNTech for patent infringement relating to the mRNA platform used to develop COVID vaccines

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.

Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine

Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty® unlawfully infringes patents Moderna filed between 2010 and 2016 Moderna not seeking removal of Comirnaty® from market or injunction against future sales Company not pursuing monetary damages on sales to the 92 low- and middle-income countries in the GAVI COVAX Advance Market Commitment (AMC 92) CAMBRIDGE, MA / ACCESSWIRE / August 26, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today is filing patent infringement lawsuits against Pfizer and BioNTech in the United States District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany. Moderna believes that Pfizer and BioNTech's COVID-19 vaccine Comirnaty® infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology.

News for Moderna Stock (MRNA)